B. Riley lowered the firm’s price target on Wave Life Sciences (WVE) to $19 from $22 and keeps a Buy rating on the shares. The firm cites FDA ...

Wave Life Sciences’ experimental treatment for Duchenne muscular dystrophy hit the mark in a mid-stage study, setting the stage for a new therapeutic option for patients.

Wave Life Sciences Ltd.’s WVE share price has dipped by 10.08%, which has investors questioning if this is right time to buy.

Wave Life Sciences’ Phase II open-label trial investigating its disease-modifying drug for boys living with Duchenne Muscular ...

Wave Life Sciences had a negative return on equity of 280.57% and a negative net margin of 66.50%. As a group, analysts forecast that Wave Life Sciences Ltd. will post -1.14 EPS for the current ...

Wedbush initiated coverage of Wave Life Sciences (WVE) with an Outperform rating and $18 price target Stay Ahead of the Market: Discover ...

Wave Life Sciences (WVE) shares ended the last trading session 6.1% higher at $10.02. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session.

Vanguard's index fund lineup continues to grow and cut costs. Here's a look at the most popular picks.

Wave Life Sciences Ltd . (NASDAQ:WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, has been making significant ...

Wave Life Sciences’ Phase II open-label trial investigating its disease-modifying drug for boys living with Duchenne Muscular Dystrophy (DMD), WVE-N531, has met all trial endpoints, showing the ...

This story is republished from STAT, the health and medicine news site that’s a partner to the Globe. Sign up for STAT’s free Morning Rounds newsletter here. Wave Life Sciences’ experimental ...